Fairvalue-Calculator Fairvalue-Calculator
EN DE

NGeneBio Co (354200) Fair Value & Analysis

Healthcare · KR · Market cap 22.8B KRW

Price792.00 KRW
Fair Value573.95 KRW
Upside-27.5%
Quality94/100
Evidence: Low Range 428.32 KRW – 856.64 KRW

Fair value as of: Jun 25, 2026

Analysis

NGeneBio Co (354200) currently trades at 792.00 KRW, while our model-based Fair Value estimate is 573.95 KRW — implying the stock looks roughly 27.5% overvalued today. We read business quality at 94/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

NGeneBio Co., Ltd. develops in vitro diagnostics companion diagnostics products and bioinformatics software. It offers BRCAaccuTest and BRCAaccuTest PLUS are reagent kits for breast and ovarian cancer, and hereditary breast and ovarian cancer syndrome; HEMEaccuTest, a clinical NGS kit for hematological malignancies, such as acute myeloid leukemia, acute lymphoid leukemia, myelodysplastic/myeloproliferative neoplasm, multiple myeloma, and lymphoma; SOLIDaccuTest, a genetic variants screening for solid tumors; HLAaccuTest, an in vitro diagnostic medical device for human leukocyte antigen typing; and OncoaccuPanel, a solid tumor oncology next generation sequencing test. The company also provides NGeneAnalySys, a software for analysis of the genetic testing data; and EasyHLAanalyzer, which offers the HLA typing identifing human leukocyte antigen for histocompatibility antigens using data from NGS. In addition, it offers MTBaccuPanel, a diagnostic panel to test mycobacterium tuberculosis…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is NGeneBio Co (354200) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 573.95 KRW versus a price of 792.00 KRW — about −28% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 354200?
Our 21-model fair value for NGeneBio Co is 573.95 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 792.00 KRW.
What is the quality score of 354200?
NGeneBio Co has a Quality Score of 94/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.